Stockreport

Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma

GENMAB A/S  (GMXAY) 
NASDAQ:AMEX Investor Relations: ir.genmab.com
PDF Company Announcement Phase III study to examine daratumumab plus lenalidomide as maintenance treatment in patients with newly diagnosed multiple myelomaStudy utilizes t [Read more]